---
---

# 21 U.S.C., USLM ref /us/usc/t21/s355b

* Portions Copyright © 2016 the authors of the https://github.com/publicdocs project.
  Use of this file is subject to the NOTICE at [https://github.com/publicdocs/uscode/blob/master/NOTICE](https://github.com/publicdocs/uscode/blob/master/NOTICE)
* See the [Document Metadata](././../../../../../..//README.md) for more information.
  This file is generated from historical government data; content and/or formatting may be inaccurate and out-of-date and should not be used for official purposes.

----------
----------

[Previous](./../../../../../..//us/usc/t21/ch9/schV/ptA/m__us_usc_t21_s355a.md) | [Next](./../../../../../..//us/usc/t21/ch9/schV/ptA/m__us_usc_t21_s355c.md) | [Root of Title](./../../../../../../) | [Other Versions of this Document](https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fusc%2Ft21%2Fs355b)

## § 355b. Adverse-event reporting

    (a) __Toll-free number in labeling__ 

    Not later than one year after January 4, 2002, the Secretary of Health and Human Services shall promulgate a final rule requiring that the labeling of each drug for which an application is approved under section 505 of the Federal Food, Drug, and Cosmetic Act \[[21 U.S.C. 355][/us/usc/t21/s355]\] (regardless of the date on which approved) include the toll-free number maintained by the Secretary for the purpose of receiving reports of adverse events regarding drugs and a statement that such number is to be used for reporting purposes only, not to receive medical advice. With respect to the final rule:

        (1) The rule shall provide for the implementation of such labeling requirement in a manner that the Secretary considers to be most likely to reach the broadest consumer audience.

        (2) In promulgating the rule, the Secretary shall seek to minimize the cost of the rule on the pharmacy profession.

        (3) The rule shall take effect not later than 60 days after the date on which the rule is promulgated.

    (b) __Drugs with pediatric market exclusivity__ 

        (1) __In general__ 

            During the one year beginning on the date on which a drug receives a period of market exclusivity under 505A  <sup>\[1\]</sup>  <sup><sup> 1 So in original. Probably should be preceded by “section”. </sup></sup>  of the Federal Food, Drug, and Cosmetic Act \[[21 U.S.C. 355a][/us/usc/t21/s355a]\], any report of an adverse event regarding the drug that the Secretary of Health and Human Services receives shall be referred to the Office of Pediatric Therapeutics established under [section 393a of this title][/us/usc/t21/s393a]. In considering the report, the Director of such Office shall provide for the review of the report by the Pediatric Advisory Committee, including obtaining any recommendations of such subcommittee  <sup>\[2\]</sup>  <sup><sup> 2 So in original. Probably should be “Committee”. </sup></sup>  regarding whether the Secretary should take action under the Federal Food, Drug, and Cosmetic Act \[[21 U.S.C. 301][/us/usc/t21/s301] et seq.\] in response to the report.

        (2) __Rule of construction__ 

            Paragraph (1) may not be construed as restricting the authority of the Secretary of Health and Human Services to continue carrying out the activities described in such paragraph regarding a drug after the one-year period described in such paragraph regarding the drug has expired.

([Pub. L. 107–109][/us/pl/107/109], § 17, Jan. 4, 2002, [115 Stat. 1422][/us/stat/115/1422]; [Pub. L. 108–155][/us/pl/108/155], § 3(b)(5), Dec. 3, 2003, [117 Stat. 1942][/us/stat/117/1942].)

 __References in Text__ 

    The Federal Food, Drug, and Cosmetic Act, referred to in subsec. (b)(1), is [act June 25, 1938, ch. 675][/us/act/1938-06-25/ch675], [52 Stat. 1040][/us/stat/52/1040], as amended, which is classified generally to this chapter. For complete classification of this Act to the Code, see [section 301 of this title][/us/usc/t21/s301] and Tables.

 __Codification__ 

    Section was enacted as part of the Best Pharmaceuticals for Children Act, and not as part of the Federal Food, Drug, and Cosmetic Act which comprises this chapter.

 __Amendments__ 

    2003—Subsec. (b)(1). [Pub. L. 108–155][/us/pl/108/155] struck out “Advisory Subcommittee of the Anti-Infective Drugs” before “Advisory Committee”.

 __Effective Date of 2003 Amendment__ 

    Amendment by [Pub. L. 108–155][/us/pl/108/155] effective Dec. 3, 2003, except as otherwise provided, see [section 4 of Pub. L. 108–155][/us/pl/108/155/s4], set out as an Effective Date note under [section 355c of this title][/us/usc/t21/s355c].

----------

[Previous](./../../../../../..//us/usc/t21/ch9/schV/ptA/m__us_usc_t21_s355a.md) | [Next](./../../../../../..//us/usc/t21/ch9/schV/ptA/m__us_usc_t21_s355c.md) | [Root of Title](./../../../../../../) | [Other Versions of this Document](https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fusc%2Ft21%2Fs355b)

----------
----------

[/us/usc/t21/s355]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fusc%2Ft21%2Fs355
[/us/usc/t21/s355a]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fusc%2Ft21%2Fs355a
[/us/usc/t21/s393a]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fusc%2Ft21%2Fs393a
[/us/usc/t21/s301]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fusc%2Ft21%2Fs301
[/us/pl/107/109]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fpl%2F107%2F109
[/us/stat/115/1422]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fstat%2F115%2F1422
[/us/pl/108/155]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fpl%2F108%2F155
[/us/stat/117/1942]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fstat%2F117%2F1942
[/us/act/1938-06-25/ch675]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fact%2F1938-06-25%2Fch675
[/us/stat/52/1040]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fstat%2F52%2F1040
[/us/usc/t21/s301]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fusc%2Ft21%2Fs301
[/us/pl/108/155]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fpl%2F108%2F155
[/us/pl/108/155]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fpl%2F108%2F155
[/us/pl/108/155/s4]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fpl%2F108%2F155%2Fs4
[/us/usc/t21/s355c]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fusc%2Ft21%2Fs355c


